Trial Profile
Effectiveness and safety of daclatasvir plus asunaprevir for chronic HCV genotype 1 infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Feb 2017 Status changed from recruiting to completed.
- 07 Dec 2015 According to University Hospital Medical Information Network - Japan record, study type changed from observational to interventional open label study.Also, planned number of patients changed from 150 to 400.
- 07 Dec 2015 Planned number of patients changed from 150 to 400, as reported by University Hospital Medical Information Network - Japan record.